Astrazeneca Net Profit Margin Growth & History (AZN)
Astrazeneca's net profit margin was 17.42% for fiscal 2025.
View full Astrazeneca company overviewAstrazeneca annual net profit margin history
| Fiscal year | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 17.42% | +4.40 pp |
| 2024 | 2024-12-31 | 13.02% | +0.01 pp |
| 2023 | 2023-12-31 | 13.01% | +5.59 pp |
| 2022 | 2022-12-31 | 7.42% | +7.12 pp |
| 2021 | 2021-12-31 | 0.31% | −11.50 pp |
| 2020 | 2020-12-31 | 11.81% | +6.78 pp |
| 2019 | 2019-12-31 | 5.03% | −4.25 pp |
| 2018 | 2018-12-31 | 9.28% | −3.49 pp |
| 2017 | 2017-12-31 | 12.77% | −2.04 pp |
| 2016 | 2016-12-31 | 14.81% | +3.37 pp |
| 2015 | 2015-12-31 | 11.44% | — |
Astrazeneca quarterly net profit margin
| Fiscal quarter | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 16.30% | −0.64 pp |
| Q1 2026 | 2026-03-31 | 20.15% | — |
| Q4 2025 | 2025-12-31 | 15.00% | — |
| Q3 2025 | 2025-09-30 | 16.67% | — |
| Q2 2025 | 2025-06-30 | 16.93% | +2.03 pp |
| Q2 2024 | 2024-06-30 | 14.90% | −1.04 pp |
| Q2 2023 | 2023-06-30 | 15.94% | +12.60 pp |
| Q2 2022 | 2022-06-30 | 3.34% | −3.35 pp |
| Q2 2021 | 2021-06-30 | 6.69% | −5.07 pp |
| Q2 2020 | 2020-06-30 | 11.76% | +9.92 pp |
| Q2 2019 | 2019-06-30 | 1.84% | −4.35 pp |
| Q2 2018 | 2018-06-30 | 6.19% | −2.64 pp |
| Q2 2017 | 2017-06-30 | 8.83% | — |
Astrazeneca net profit margin trends
Over the last five fiscal years, Astrazeneca's net profit margin increased from 11.81% to 17.42%, a change of +5.61 percentage points. The latest reported quarter, Q2 2026, shows 16.30%.
What net profit margin means
Net profit margin measures the percentage of revenue remaining as net income after operating costs, interest, taxes, and other expenses. It shows how much bottom-line profit or loss a company generates from each dollar of revenue.
How net profit margin is calculated
TickerStat calculates net profit margin as SEC-reported net income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Astrazeneca source filings ↗Community posts
AstraZeneca receives US accelerated approval for Etcamah in a defined breast-cancer setting
AstraZeneca announced US accelerated approval of Etcamah on 7 September 2026. Approved setting Camizestrant, combined with a CDK4/6 inhibitor, is approved for adults with HR-positive, HER2-negative locally advanced or metastatic breast canc ...